Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: A meta-analysis based on updated individual patient data from six medical centers in mainland China
Wu YL Zhong WZ Li LY et al. Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol 2007;2:430-439.
Biomarker analyses from a phase III randomized open-label first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS
Fukuoka M Wu Y Thongprasert S et al. Biomarker analyses from a phase III randomized open-label first-line study of gefitinib versus carboplatin/ paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Engelman JA Zejnullahu K Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-1043.
Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer
Dziadziuszko R Wynes MW Singh S et al. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 2012;7:340-347.
High MET copy number and MET overexpression: Poor outcome in non-small cell lung cancer patients
Park S Choi YL Sung CO et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012;27:197-207.
Final results from OAM4558g a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC
abstr 7505
Spigel DR Ervin TJ Ramlau R et al. Final results from OAM4558g a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29 (suppl): abstr 7505
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
Kubo T Yamamoto H Lockwood WW et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009;124:1778-1784.
Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells
Xu L Nilsson MB Saintigny P et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010;29:2616-2627.
C-MET/Phospho-MET protein expression and MET gene copy number in non-small cell lung cancer
Tsuta K Kozu K Mimae T et al. c-MET/Phospho-MET protein expression and MET gene copy number in non-small cell lung cancer. J Thorac Oncol 2012;7: 331-339.
A selective small molecule c-MET Inhibitor PHA665752 cooperates with rapamycin
Ma PC Schaefer E Christensen JG Salgia R. A selective small molecule c-MET Inhibitor PHA665752 cooperates with rapamycin. Clin Cancer Res 2005;11:2312-2319.
A selective small molecule inhibitor of c-Met PHA-665752 reverses lung premalignancy induced by mutant K-ras
Yang Y Wislez M Fujimoto N et al. A selective small molecule inhibitor of c-Met PHA-665752 reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 2008;7:952-960.
Phase i trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies
Yap TA Olmos D Brunetto AT et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-1279.
Activity of crizotinib (PF02341066) a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor in a non-small cell lung cancer patient with de novo MET amplification
Ou SH Kwak EL Siwak-Tapp C et al. Activity of crizotinib (PF02341066) a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6:942-946.
